Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Emergency Protocol Activation – V 2.0

Posted on By

BA-BE Studies: SOP for Emergency Protocol Activation – V 2.0

Standard Operating Procedure for Emergency Protocol Activation in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/134/2025
Supersedes SOP/BA-BE/134/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a clear and effective procedure for the activation and management of emergency protocols during the conduct of BA/BE studies in order to ensure immediate response, subject safety, and adherence to regulatory obligations.

2. Scope

This SOP is applicable to all staff at clinical and bioanalytical trial facilities involved in the conduct of BA/BE studies during any medical, technical, or environmental emergency.

3. Responsibilities

  • Principal Investigator (PI):
Oversees emergency management and ensures subject safety.
  • Medical Officer: Provides immediate medical care and documents clinical management.
  • Study Coordinator: Assists in communication, coordination, and execution of response activities.
  • QA Personnel: Ensures all emergency actions are documented and reviewed per GCP and site SOPs.
  • 4. Accountability

    The Clinical Operations Head is accountable for ensuring timely activation, documentation, and reporting of emergency procedures in accordance with regulatory and ethical guidelines.

    5. Procedure

    5.1 Definition of Emergency

    1. Medical emergencies (e.g., severe allergic reaction, cardiac arrest, seizures)
    2. Operational emergencies (e.g., power failure, equipment breakdown)
    3. Environmental hazards (e.g., fire, flooding, gas leaks)

    5.2 Activation of Emergency Protocol

    1. Any staff member identifying an emergency must immediately inform the Medical Officer or PI.
    2. Activate Annexure-1: Emergency Protocol Activation Checklist.
    3. Use public announcement system or designated emergency signal where applicable.

    5.3 Subject Management During Emergency

    1. Stabilize affected subject(s) using emergency equipment (e.g., oxygen, defibrillator).
    2. Move subject to designated emergency care room.
    3. Document event in Annexure-2: Emergency Incident Report Form.
    4. Inform local emergency medical services if required.

    5.4 Evacuation and Site Safety

    1. Follow Annexure-3: Site Evacuation Plan in case of fire or environmental threat.
    2. Ensure all subjects and staff evacuate in an orderly manner.
    3. Assemble at pre-identified muster points and perform headcount.

    5.5 Communication and Notification

    1. Notify:
      • Sponsor/monitor within 24 hours
      • IEC/IRB within the required reporting timeline
      • Regulatory authority (e.g., CDSCO) for SAEs or critical incidents
    2. Use Annexure-4: Regulatory Notification Form.

    5.6 Post-Emergency Review and CAPA

    1. Conduct emergency debrief within 48 hours with all involved staff.
    2. Initiate CAPA using Annexure-5: Emergency CAPA Log.
    3. Review procedures to identify gaps or retraining needs.

    6. Abbreviations

    • PI: Principal Investigator
    • IEC: Institutional Ethics Committee
    • SAE: Serious Adverse Event
    • CAPA: Corrective and Preventive Action
    • CDSCO: Central Drugs Standard Control Organization

    7. Documents

    1. Emergency Protocol Activation Checklist – Annexure-1
    2. Emergency Incident Report Form – Annexure-2
    3. Site Evacuation Plan – Annexure-3
    4. Regulatory Notification Form – Annexure-4
    5. Emergency CAPA Log – Annexure-5

    8. References

    • ICH E6(R2) – Good Clinical Practice
    • Schedule Y – Drugs and Cosmetics Rules, India
    • WHO Emergency Response Framework

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Emergency Protocol Activation Checklist

    Step Description Status Initials
    1 Identify and report emergency Completed SR
    2 Alert medical response team Completed AV

    Annexure-2: Emergency Incident Report Form

    Date Time Type of Emergency Subject ID Description Action Taken
    16/04/2025 11:30 AM Anaphylaxis SUB012 Allergic reaction post-dose Administered epinephrine

    Annexure-3: Site Evacuation Plan

    Zone Exit Route Muster Point Supervisor
    Dosing Room North Stairwell Assembly Zone A Meena Joshi

    Annexure-4: Regulatory Notification Form

    Notified To Date Mode Details Sent Acknowledged By
    IEC Chair 16/04/2025 Email SAE Report, PI statement Dr. Ramesh Kumar

    Annexure-5: Emergency CAPA Log

    Date Issue Root Cause Corrective Action Preventive Action Status
    17/04/2025 Delayed response Alarm not triggered Manual alert issued Install new alert system Ongoing

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    05/01/2022 1.0 Initial SOP release Trial SOP setup QA Head
    17/04/2025 2.0 Added structured annexures and evacuation protocols Inspection feedback QA Head
    See also  BA-BE Studies: SOP for Regulatory Submission Planning for BE Studies - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: Analytical Method Development: Gas Evolution Reaction Method – V 2.0
    Next Post: Elixir Department: SOP for Use of Water for Injection (WFI) in Elixir Production – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version